Detects human Thrombopoietin R/Tpo R in direct ELISAs and Western blots. In direct ELISAs and Western blots, less than 1% cross‑reactivity with recombinant human Epo R is observed.
Polyclonal Goat IgG
Mouse myeloma cell line NS0-derived recombinant human Thrombopoietin R/Tpo R Gln26-Tyr423 Accession # P40238
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
<0.10 EU per 1 μg of the antibody by the LAL method.
Recombinant Human Thrombopoietin R/Tpo R (Catalog # 4444-TR)
Measured by its ability to neutralize Thrombopoietin/Tpo-induced proliferation in the MO7e human megakaryocytic leukemic cell line. Avanzi, G. et al. (1988) Br. J. Haematol. 69:359. The Neutralization Dose (ND50) is typically 0.5‑2.5 µg/mL in the presence of 10 ng/mL Recombinant Human Thrombopoietin/Tpo.
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Cell Proliferation Induced by Thrombopoietin/Tpo and Neutralization by Human Thrombopoietin R/Tpo R Antibody.
Recombinant Human Thrombopoietin/Tpo (Catalog # 288-TP) stimulates proliferation in the MO7e human megakaryocytic leukemic cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human Thrombopoietin/Tpo (10 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human Thrombopoietin R/Tpo R Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1016). The ND50 is typically 0.5‑2.5 µg/mL.
Preparation and Storage
Reconstitute at 0.2 mg/mL in sterile PBS.
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: Thrombopoietin R/Tpo R
Thrombopoietin receptor (Tpo R), also known as myeloproliferative leukemia protein (c-mpl), is a 95 kDa type I transmembrane protein that is a member of the type I cytokine receptor family within the hematopoietin/cytokine receptor superfamily (1‑4). The 635 amino acid (aa) full-length human Tpo R contains a 25 aa signal sequence, a 466 aa extracellular domain with a ligand binding domain and two fibronectin type III domains, a transmembrane (TM) domain and a cytoplasmic domain. The extracellular domain of human Tpo R shares 78%, 76%, 81%, 82% and 80% aa identity with mouse, rat, bovine, canine and equine Tpo R, respectively. Humans produce three distinct mRNA species; a P-form, a K-form, and a truncated form (Mpl-tr) lacking a TM domain (3‑7). The P-form encodes the full-length receptor. The Mpl-tr form, which is expressed in both human and mouse, is intracellular and targets the P-form for degradation (5, 6). The 579 aa K-form has an alternate cytoplasmic domain, but does not dimerize with, or inhibit, the P-form (7). Thrombopoietin (Tpo) is a key regulator of megakaryocytopoiesis, thrombopoiesis and hematopoietic stem cell self-renewal, as reflected by expression of the Tpo R on megakaryocytes, platelets and hematopoietic progenitors (2, 8). Receptor dimerization occurs upon Tpo binding and initiates signaling through the Ras/MAP and JAK/STAT pathways (1, 2). Internalization and degradation of Tpo following Tpo R binding serves to downregulate circulating Tpo (9). Tpo R expressed at low levels on endothelial cells does not appear to contribute to regulation of Tpo (10). Inactivating mutations of Tpo R cause thrombocytopenia, and absence of functional Tpo R is lethal in humans, but not mice. Other mutations, including an activating change in the TM domain, can cause thrombocytosis (11, 12).
Kaushansky, K. (2005) J. Clin. Invest. 115:3339.
Deutsch, V.R. and A. Tomer (2006) Br. J. Haematol. 134:453.
Vigon, I. et al. (1992) Proc. Natl. Acad. Sci. USA 89:5640.
Mignotte, V. et al. (1994) Genomics 20:5.
Li, J. et al. (2000) Cytokine 12:835.
Coers, J. et al. (2004) J. Biol. Chem. 279:36397.
Millot, G.A. et al. (2002) Exp. Hematol. 30:166.
Tong, W. et al. (2007) Exp. Hematol. July 14 [Epub ahead of print].
Li, J. et al. (1999) Br. J. Haematol. 106:345.
Geddis, A.E. et al. (2006) Exp. Hematol. 34:82.
Germeshausen, M. et al. (2006) Hum. Mutat. 27:296.
R&D Systems personnel manually curate a database that contains references using R&D Systems products.
The data collected includes not only links to publications in PubMed,
but also provides information about sample types, species, and experimental conditions.
Have you used Human Thrombopoietin R/Tpo R Antibody?
Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.